X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs BIOCON - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA BIOCON GLENMARK PHARMA/
BIOCON
 
P/E (TTM) x 19.1 41.8 45.6% View Chart
P/BV x 3.4 7.3 46.6% View Chart
Dividend Yield % 0.3 0.2 194.9%  

Financials

 GLENMARK PHARMA   BIOCON
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
BIOCON
Mar-18
GLENMARK PHARMA/
BIOCON
5-Yr Chart
Click to enlarge
High Rs9301,188 78.3%   
Low Rs517305 169.6%   
Sales per share (Unadj.) Rs322.668.7 469.4%  
Earnings per share (Unadj.) Rs28.57.6 377.3%  
Cash flow per share (Unadj.) Rs39.214.0 280.5%  
Dividends per share (Unadj.) Rs2.001.00 200.0%  
Dividend yield (eoy) %0.30.1 206.3%  
Book value per share (Unadj.) Rs183.086.3 211.9%  
Shares outstanding (eoy) m282.17600.00 47.0%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x2.210.9 20.7%   
Avg P/E ratio x25.498.9 25.7%  
P/CF ratio (eoy) x18.553.4 34.6%  
Price / Book Value ratio x4.08.6 45.7%  
Dividend payout %7.013.2 53.0%   
Avg Mkt Cap Rs m204,206447,900 45.6%   
No. of employees `00013.76.1 223.1%   
Total wages/salary Rs m18,7189,311 201.0%   
Avg. sales/employee Rs Th6,636.86,705.8 99.0%   
Avg. wages/employee Rs Th1,364.71,514.2 90.1%   
Avg. net profit/employee Rs Th586.1736.9 79.5%   
INCOME DATA
Net Sales Rs m91,03141,234 220.8%  
Other income Rs m9142,062 44.3%   
Total revenues Rs m91,94543,296 212.4%   
Gross profit Rs m16,1548,291 194.8%  
Depreciation Rs m3,0193,851 78.4%   
Interest Rs m2,856615 464.3%   
Profit before tax Rs m11,1935,887 190.1%   
Minority Interest Rs m0213 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,1551,569 201.1%   
Profit after tax Rs m8,0394,531 177.4%  
Gross profit margin %17.720.1 88.3%  
Effective tax rate %28.226.7 105.7%   
Net profit margin %8.811.0 80.4%  
BALANCE SHEET DATA
Current assets Rs m69,88741,486 168.5%   
Current liabilities Rs m32,87921,413 153.5%   
Net working cap to sales %40.748.7 83.5%  
Current ratio x2.11.9 109.7%  
Inventory Days Days8164 127.3%  
Debtors Days Days9394 99.3%  
Net fixed assets Rs m28,89250,661 57.0%   
Share capital Rs m2823,000 9.4%   
"Free" reserves Rs m51,35348,808 105.2%   
Net worth Rs m51,63551,808 99.7%   
Long term debt Rs m41,41817,898 231.4%   
Total assets Rs m125,95499,897 126.1%  
Interest coverage x4.910.6 46.5%   
Debt to equity ratio x0.80.3 232.2%  
Sales to assets ratio x0.70.4 175.1%   
Return on assets %8.65.2 167.9%  
Return on equity %15.68.7 178.0%  
Return on capital %15.19.6 156.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36,31712,058 301.2%   
Fx outflow Rs m9,7207,348 132.3%   
Net fx Rs m26,5984,710 564.7%   
CASH FLOW
From Operations Rs m16,4816,621 248.9%  
From Investments Rs m-10,133-6,840 148.1%  
From Financial Activity Rs m-4,685-2,397 195.5%  
Net Cashflow Rs m1,770-2,612 -67.8%  

Share Holding

Indian Promoters % 48.3 40.4 119.6%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 6.9 8.4 82.1%  
FIIs % 34.4 10.7 321.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 19.9 52.8%  
Shareholders   56,727 109,995 51.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   STRIDES PHARMA SCIENCE  ELDER PHARMA  VENUS REMEDIES  ALKEM LABORATORIES  AJANTA PHARMA  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Marginally Higher; Realty and Energy Stocks Witness Buying(Closing)

Indian share markets witnessed volatility during closing hours and ended their day marginally higher. Gains were largely seen in the realty sector.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

More Views on News

Most Popular

Are You Ready for the Big Nifty Move in the March Expiry?(Profit Hunter)

Mar 8, 2019

History suggests the Nifty could make a big move in March. Are you prepared to benefit from this opportunity?

Smallcaps Are Rallying and You Need to Make the Most of It Now(Profit Hunter)

Mar 7, 2019

Did you just miss the smallcap rally? Or is there still time to catch up? Read on for answers and more...

The One Sector to Bet on Today as India Grows into a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Mar 7, 2019

India's defence sector is suddenly under the spotlight. Can this sector ride along India's long-term growth story?

Is it the Right Time to Buy Mid and Small Caps Now?(The 5 Minute Wrapup)

Mar 6, 2019

Mid and Small Caps have underperformed large caps in the past year. Is the tide about to turn?

The Jet Airways Crisis in 6 Charts(Sector Info)

Mar 5, 2019

What happened to Jet Airways, once among top 3 airlines in India? Is it another Kingfisher in the making? Read on...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Mar 18, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS